The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia.
OBJECTIVE
To evaluate the effects of combined tamoxifen citrate and T undecanoate treatment on seminal parameters in men with idiopathic oligozoospermia.


METHODS
Prospective randomized clinical study.


METHODS
A state hospital tertiary clinic.


METHODS
Eighty oligozoospermic men were included in the protocol.


METHODS
Patients were randomized to receive placebo, T undecanoate (40 mg three times per day), tamoxifen citrate (10 mg two times per day), or T undecanoate plus tamoxifen citrate.


RESULTS
Tamoxifen citrate plus T undecanoate treatment produced a satisfactory improvement of total sperm number, motility, and functional sperm fraction after 3 and 6 months. Comparisons with other active treatment groups showed significantly higher increment values for motility and functional fraction, whereas aniline, acrosine, and free L-carnitine also were markedly better in the combination treatment group.


CONCLUSIONS
These results indicate that the combination of tamoxifen citrate with T undecanoate not only improves significantly important seminal parameters but also compares favorably with the single treatments used. Therefore, this combination deserves a place as a first line of treatment in idiopathic oligozoospermia.
Adamopoulos
D A
DA
Endocrine Department, Elena Venizelou Hospital, Athens, Greece.
Nicopoulou
S
S
Kapolla
N
N
Karamertzanis
M
M
Andreou
E
E
D000176:Acrosin / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D000814:Aniline Compounds / Q000032:analysis / Q000378:metabolism; D002331:Carnitine / Q000032:analysis / Q000378:metabolism; D015331:Cohort Studies; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009845:Oligospermia / Q000188:drug therapy*; D011446:Prospective Studies; D013076:Sperm Count / Q000187:drug effects; D013081:Sperm Motility / Q000187:drug effects / Q000502:physiology; D013094:Spermatozoa / Q000737:chemistry / Q000187:drug effects* / Q000201:enzymology; D013629:Tamoxifen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D045165:Testosterone Congeners / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000814:Aniline Compounds; D004965:Estrogen Antagonists; D045165:Testosterone Congeners; D013629:Tamoxifen; D013739:Testosterone; D000176:Acrosin; C010792:testosterone undecanoate; D002331:Carnitine; C023650:aniline